Exelixis, Inc. (EXEL)
EXEL Stock Price Chart
Explore Exelixis, Inc. interactive price chart. Choose custom timeframes to analyze EXEL price movements and trends.
EXEL Company Profile
Discover essential business fundamentals and corporate details for Exelixis, Inc. (EXEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Apr 2000
Employees
1.15K
Website
https://www.exelixis.comCEO
Michael M. Morrissey
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EXEL Financial Timeline
Browse a chronological timeline of Exelixis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.68.
Earnings released on 28 Jul 2025
EPS came in at $0.75 surpassing the estimated $0.65 by +15.38%, while revenue for the quarter reached $568.26M , missing expectations by -4.48%.
Earnings released on 13 May 2025
EPS came in at $0.62 surpassing the estimated $0.36 by +73.14%, while revenue for the quarter reached $555.45M , beating expectations by +11.18%.
Earnings released on 11 Feb 2025
EPS came in at $0.55 surpassing the estimated $0.51 by +7.84%, while revenue for the quarter reached $566.76M , beating expectations by +0.63%.
Earnings released on 29 Oct 2024
EPS came in at $0.47 surpassing the estimated $0.42 by +11.90%, while revenue for the quarter reached $539.54M , missing expectations by -3.06%.
Earnings released on 6 Aug 2024
EPS came in at $0.84 surpassing the estimated $0.37 by +127.03%, while revenue for the quarter reached $637.18M , beating expectations by +37.03%.
Earnings released on 30 Apr 2024
EPS came in at $0.17 falling short of the estimated $0.28 by -39.29%, while revenue for the quarter reached $425.23M , missing expectations by -7.68%.
Earnings released on 6 Feb 2024
EPS came in at $0.33 surpassing the estimated $0.31 by +6.45%, while revenue for the quarter reached $479.65M , missing expectations by -0.11%.
Earnings released on 1 Nov 2023
EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $471.92M , beating expectations by +0.01%.
Earnings released on 1 Aug 2023
EPS came in at $0.31 surpassing the estimated $0.22 by +40.91%, while revenue for the quarter reached $469.85M , beating expectations by +4.96%.
Earnings released on 9 May 2023
EPS came in at $0.16 falling short of the estimated $0.23 by -30.43%, while revenue for the quarter reached $408.79M , missing expectations by -3.61%.
Earnings released on 7 Feb 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $423.92M , beating expectations by +1.51%.
Earnings released on 1 Nov 2022
EPS came in at $0.31 surpassing the estimated $0.25 by +24.00%, while revenue for the quarter reached $411.74M , beating expectations by +2.05%.
Earnings released on 9 Aug 2022
EPS came in at $0.22 surpassing the estimated $0.20 by +10.00%, while revenue for the quarter reached $419.43M , beating expectations by +7.26%.
Earnings released on 10 May 2022
EPS came in at $0.21 surpassing the estimated $0.14 by +50.00%, while revenue for the quarter reached $355.98M , missing expectations by -4.93%.
Earnings released on 17 Feb 2022
EPS came in at $0.29 surpassing the estimated $0.07 by +314.29%, while revenue for the quarter reached $451.14M , beating expectations by +26.80%.
Earnings released on 2 Nov 2021
EPS came in at $0.12 falling short of the estimated $0.19 by -36.84%, while revenue for the quarter reached $328.42M , missing expectations by -5.01%.
Earnings released on 5 Aug 2021
EPS came in at $0.30 surpassing the estimated $0.05 by +500.00%, while revenue for the quarter reached $385.18M , beating expectations by +30.35%.
Earnings released on 6 May 2021
EPS came in at $0.01 , while revenue for the quarter reached $270.23M , beating expectations by +2.59%.
Earnings released on 10 Feb 2021
EPS came in at $0.09 surpassing the estimated $0.05 by +70.68%, while revenue for the quarter reached $270.05M , beating expectations by +34.68%.
Earnings released on 5 Nov 2020
EPS came in at -$0.10 falling short of the estimated -$0.05 by -100.00%, while revenue for the quarter reached $231.09M , beating expectations by +900.00%.
EXEL Stock Performance
Access detailed EXEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.